NEW OR RETURNING USERS: SIGN IN  |   UPDATE PROFILE  |   CME/CE TRACKER    



  

Ophthalmology

What's New in AMD Therapy for the Practice Manager
This CME/CE activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.

Click here to view our current activities in Ophthalmology.

What's New in Age-related Macular Degeneration (AMD) Therapy for the Practice Manager
Free 1-hour CME/CE Webcast Featuring Expert Faculty

Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in Americans. With our population aging, the number of people with AMD is on the rise.

This activity is directed to practice managers involved in the care of patients with AMD.

MODERATOR
Kirk A. Mack, COE, CPC, COMT
Senior Consultant
Corcoran Consulting Group
San Bernardino, CA

FACULTY
Alexander M. Stockdale, MBA
Chief Executive Officer
Southeastern Retina Associates
Knoxville, TN

Ivan J. Suñer, MD
Associate Professor of Ophthalmology
Duke University Medical Center
  (Duke Eye Center)
Chief of Ophthalmology Service
Durham Veterans Affairs Medical Center
Durham, NC
top

TARGET AUDIENCE
This CME/CE activity will be directed to practice managers involved in the care of patients with AMD.

ACTIVITY GOAL
The goal of this CME/CE activity is to review the scientific and practical business aspects of managing patients with AMD.

LEARNING OBJECTIVES
  • Utilizing a knowledge of AMD and the efficacy and safety/toxicity implications of new targeted therapies, formulate anti-VEGF therapies into regimens to improve patients’ vision outcomes.

  • By integrating an understanding of billing pitfalls with new therapies, create and institute more efficient billing methods.

  • Identify and evaluate strategies for incorporating efficiencies into the practice setting to obtain reimbursement for patient services, including new anti-VEGF therapies.
ACTIVITY AGENDA

Kirk A. Mack, COE, CPC, COMT: Introduction
Ivan J. Suñer, MD: State-of-the-Science: Treatment of Neovascular AMD
  • Overview of AMD
  • Current Therapies in the Treatment of AMD
  • How to Implement AMD Care: Clinical Application Including Safety Issues
Alexander M. Stockdale, MBA: Implications of Anti-VEGF Therapies in Managed Care: Avoiding Billing Pitfalls
  • Approved Therapies
  • Combination Therapies
  • State to State & Carrier to Carrier Issues
Kirk A. Mack, COE, CPC, COMT: Implications of Anti-VEGF Therapies in Managed Care: Reimbursement Strategies
  • Medicare and Commercial Coverage
  • On Label/Off Label: Implications for Reimbursement
  • Frequency of Injections/Concomitant Procedure Issues
  • Adequate Clinical Information and Documentation

Assigned Faculty: Q & A
top

CME INFORMATION

STATEMENT OF ACCREDITATION: PHYSICIANS
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

CE INFORMATION

STATEMENT OF ACCREDITATION: Managed Care (ACMPE)
This program may qualify for continuing education credit in the American College of Medical Practice Executives (ACMPE). To apply for ACMPE credit, submit an ACMPE generic credit hour form with a copy of this program agenda.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
top

DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Kirk A. Mack, COE, CPC, COMT, has disclosed no significant relationships. Mr. Mack has disclosed that he will reference the unlabeled or unapproved use of bevacizumab.

Alexander M. Stockdale, MBA, is on the speakers bureau of Eyetech/OSI Pharmaceuticals and is on advisory boards for Genentech, Inc and International Vision Network. Mr. Stockdale has disclosed that he will reference the unlabeled or unapproved use of bevacizumab for CNV.

Ivan J. Suñer, MD, has received grants from Genentech, Inc and Optos Plc; is a consultant for Bausch & Lomb, Inc, Genentech, Inc, Optos Plc, OSI Eyetech, and Pfizer Inc; is on the speakers bureau of Bausch & Lomb, Inc, Genentech, Inc, Optos Plc, OSI Eyetech, and Pfizer Inc; and has received consulting fees from Genentech, Inc, OSI Eyetech, and Pfizer Inc. Dr. Suner has disclosed that he will reference the unlabeled or unapproved use of bevacizamab.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Click here for TECHNICAL REQUIREMENTS

This independent CME activity is supported by an educational grant from
Reliant Pharmaceuticals, Inc.
top

1772
 

 
Program Information

Faculty
Target Audience
Activity Goal
Learning Objectives
CME Information
Disclosure Information
Technical Requirements

By clicking below, I certify that I have read the accompanying CME/CE and disclosure information and am ready to continue to this activity.

Release Date: August 8, 2006.

Termination Date: August 8, 2007.

Estimated Time for Completion of this Activity: 1.0 hour.



Recommend this page
Recommend this to a colleague


This independent CME/CE activity is supported by an educational grant from Genentech, Inc.



ABOUT US CONTACT US CONTRACT DIRECTIONS PRIVACY POLICY RESOURCES
Copyright © 1997-2008, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988